Pharma BD Deal Intelligence
A $5.3B acquisition that gave BMS an injectable diabetes portfolio (Byetta/Bydureon) but delivered a partially-achieved outcome, with financial return the weakest dimension of the deal. Strategic fit was sound, though integration and pipeline payoff never matched the price tag.
BMS / Amylin Pharmaceuticals: Partially Achieved (Score: 46/100)
Full analysis, sources & comparables →BMS acquired Amylin Pharmaceuticals for $5.3B for diabetes treatment portfolio.
AstraZeneca made a $3.4 billion cash payment as part of Bristol-Myers Squibb's acquisition of Amylin Pharmaceuticals, making Amylin a wholly owned subsidiary…
Bristol-Myers Squibb agreed to acquire Amylin Pharmaceuticals for $31 per share or approximately $5.3 billion, with total transaction value of about $7 billion…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS acquired Amylin Pharmaceuticals for $5.3B for diabetes treatment portfolio.
BMS / Amylin Pharmaceuticals: Partially Achieved (Score: 46/100)
Assessment window: 5yr post-close.
21M US cases/yr · $16.0B US Diabetes Therapeutics Market (2012) · $7B Total Transaction Value (incl. debt)
Amylin pioneered GLP-1 agonist therapy with Byetta (2005) and Bydureon (approved Jan 2012). BMS's $5.3B acquisition ($7B total) added these to the BMS-AZ diabetes alliance. GLP-1 agonists became one of pharma's most important drug classes.
AZ took full ownership in 2014. Bydureon achieved ~$600M peak but was eclipsed by Victoza/Ozempic (semaglutide). The GLP-1 class exploded to >$40B annually by 2024 driven by weight loss (Wegovy, Mounjaro). Amylin's pioneering role established the class but did not capture its eventual value.
Bristol-Myers Squibb Co. closes acquisition/merger of Amylin Pharmaceuticals for $5.3B, establishing strategic position and initiating integration.
Strategic Fit: 65/100 | Financial Return: 35/100 | Pipeline Outcome: 40/100 | Integration: 45/100 | Deal Difficulty: 55/100. Partially Achieved overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Amylin Pharmaceuticals (this deal) | 2012 | $5.3B | 39 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2012 deals · Bristol-Myers Squibb Company deals · Metabolic deals